Potential Pandemics in 2026: Which Viruses Could Emerge
What is the Current Status of the COVID-19 Pandemic?
Table of Contents
As of January 12,2026,the COVID-19 pandemic is considered to be in an endemic phase globally,though continued monitoring and vaccination remain crucial due to the emergence of new variants and potential for localized outbreaks.
The transition to endemicity doesn’t signify the end of the virus, but rather a shift in how societies manage it. This means COVID-19 is expected to continue circulating, similar to influenza, with seasonal increases in cases. the World Health Institution (WHO) officially declared that COVID-19 no longer constitutes a Public Health Emergency of International Concern (PHEIC) on May 5, 2023, signaling a important step in this transition. However,the WHO continues to monitor the virus and provide guidance to member states.
Such as, the Centers for Disease Control and Prevention (CDC) in the United States updated its COVID-19 guidance in March 2024, focusing on individual risk assessment and preventative measures like vaccination and improved ventilation, rather than broad, mandatory restrictions. CDC COVID-19 information
What are the Dominant COVID-19 Variants in 2026?
Currently, the EG.5 (Eris) and its sublineages, along with the newer JN.1 variant, are the dominant strains of SARS-CoV-2 circulating globally as of late 2023 and early 2026. Thes variants demonstrate increased transmissibility but do not appear to cause more severe illness than previous strains in vaccinated individuals.
The emergence of these variants highlights the virusS continued ability to mutate. JN.1, a descendant of BA.2.86 (Pirola),gained prominence in December 2023 due to its rapid spread. Scientists are continuously monitoring these variants for changes in their characteristics, including immune evasion and disease severity. The WHO maintains a list of Variants of Interest (VOI) and Variants of Concern (VOC) based on these factors.
Data from the European Center for Disease Prevention and Control (ECDC) indicates that JN.1 accounted for approximately 60-70% of cases reported in Europe by january 2026. ECDC COVID-19 Variants
How Effective are Current COVID-19 Vaccines?
Updated COVID-19 vaccines, formulated to target current variants like JN.1, continue to provide significant protection against severe illness, hospitalization, and death. While vaccine effectiveness against infection has decreased due to viral evolution, protection against serious outcomes remains robust, notably after receiving booster doses.
the FDA authorized updated COVID-19 vaccines in September 2023, and again in June 2024, to address the evolving virus. These vaccines are designed to elicit a broader immune response, offering better protection against a wider range of variants. The CDC recommends that everyone ages 6 months and older receive an updated 2024-2025 COVID-19 vaccine, regardless of prior vaccination status.
A study published in the *New England journal of Medicine* in February 2025 showed that individuals who received the updated 2024-2025 vaccine experienced a 75% reduction in the risk of hospitalization compared to unvaccinated individuals.New England journal of Medicine (search for relevant COVID-19 vaccine studies)
What are the Current Treatment Options for COVID-19?
Several effective treatments for COVID-19 are available, including antiviral medications like Paxlovid and Molnupiravir, as well as monoclonal antibody therapies, though the efficacy of some monoclonal antibodies has diminished with the emergence of new variants. Treatment decisions are based on individual risk factors and disease severity.
Paxlovid, an oral antiviral, remains a primary treatment option for high-risk individuals experiencing mild to moderate COVID-19 symptoms. It has been shown to substantially reduce the risk of hospitalization and death when administered within five days of symptom onset. However, drug interactions are a consideration when prescribing Paxlovid.
The National Institutes of Health (NIH) provides updated guidelines on the management of COVID-19, including treatment recommendations. NIH COVID-19 Treatment Guidelines. As of December 2025, the NIH recommends prioritizing Paxlovid for eligible patients and considering alternative therapies when Paxlovid is not appropriate.